Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Cisplatin + Fluorouracil (5-FU) + Pembrolizumab & Gastric Cancer / Gastric adenocarcinoma / Stomach cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Regulatory status:

In the context of Cthe randomized, double-blind, placebocontrolled, Phase III KEYNOTE-859 study,isplatin + Fluorouracil (5-FU) + Pembrolizumab & Gastric Cancer / Gastric adenocarcinoma / Stomach cancer, there is an FDA and EMA approval that covers Cisplatin + Fluorouracil (5-FU) + Pembrolizumab as first‑line therapy for Gastric Cancer / Gastric adenocarcinoma / Stomach cancer / gastroesophageal cancers, but the wording is usually broader (“fluoropyrimidine‑ and platinum‑containing chemotherapy”) rath…

References (Sources)

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. 2018
Review
KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Rha et al. 2025 J Clin Oncol 43: 4036-4036
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Tabernero et al. 2021a Future Oncol 17(22): 2847-2855
Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
Rha et al. 2024 J Clin Oncol 42: 4045-4045

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!